Invasive Histoplasmosis Presenting as Tenosynovitis in an Immunocompromised Patient
A patient with a history of lupus nephritis initially presented with right hand and arm symptoms that were attributed to a lupus flare. However, eight months later, the patient experienced increasing pain and edema in his right hand, leading to a diagnosis of Histoplasma tenosynovitis.
Testing for Viral Respiratory Illnesses: Best Practices, Types of Tests, Advantages and Drawbacks, and Patient/Provider Education
This discussion revolves around diagnostics for viruses and best practices and challenges.
Political and Social Barriers to Ending the HIV Epidemic
Learning about these barriers is the first step to overcoming them.
Exploring the Recently Approved and Upcoming Clostridioides difficile Therapeutics
This market has seen a flurry of activity, as shown by a review of the latest agents.
Outpatient Antimicrobial Stewardship: The Keys to Developing a Successful Program
This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
Communication Breakdown: Dissemination of Public Health Information
Imprecise language can fuel infodemics and misinformation and damage public trust.
Should Linezolid Replace Clindamycin for Necrotizing Soft Tissue Infections?
A comparative study found that using linezolid in place of clindamycin in combination with vancomycin for the treatment of necrotizing soft tissue infections resulted in similar 30-day mortality rates but lower rates of acute kidney injury and composite adverse outcomes, suggesting the effectiveness and safety of linezolid as an alternative therapy.
Need for Speed: Rapid Antiretroviral Initiation in the Emergency Department
Emergency departments (EDs) are an important entry point into the health care
system and have been identified as a location with opportunity for increased HIV diagnosis and management.
What’s New in 2023 From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
This year's Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing provided updated breakpoints on therapies.
Sulbactam/Durlobactam: Can a Branded, Targeted Antimicrobial for a Single, Resistant Pathogen Succeed?
In the October Editor-in-Chief letter, Jason Gallagher PharmD, FCCP,
FIDP, FIDSA, BCPS, writes about this novel antibiotic indicated for a targeted, resistant pathogen and its long-term viability.
Emerging β-Lactamases in Pseudomonas aeruginosa That Threaten the Utility of New β-Lactam/β-Lactamase Inhibitors
Resistance against this pathogen with β-lactamase medications
can vary according to geographic region.
2 Clarke Drive Cranbury, NJ 08512